Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
Small neurotrophic-mimetic peptide from CNTF research; preclinical only.
Also known as: P021 · CNTF-derived peptide
Part of the Neuropeptides & signaling cluster
Overview
P21 (P021) is a synthetic peptide designed as a mimetic of an active region of ciliary neurotrophic factor (CNTF). It has been studied in animal models of neurogenesis and cognitive aging and is not authorized as a medicine by Health Canada.
Source & context
Biological / chemical source: Synthetic mimetic of a ciliary neurotrophic factor (CNTF) region
Primary research or clinical context: Preclinical research compound (not authorized by Health Canada)
Design concept
Researchers reduced the active region of CNTF to a short, chemically stabilized peptide intended to cross the blood–brain barrier. The core is an acetylated tetrapeptide bearing an adamantane modification, illustrating peptidomimetic design strategies.
Evidence status
Published findings on P21 come from preclinical rodent studies, including models of Alzheimer-type pathology and cognitive aging. There are no completed human clinical trials, and this page does not present it as a treatment.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- P21 (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C27H42N6O8
- Average reference mass
- ≈ 578.7
- PubChem CID: 56599151
- IUPHAR ligand: 5250
- CAS RN: 1246751-68-7
- UNII: VV8CZC8PAS
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 9 registered studies with “P21” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc | Phase 2 | active not recruiting | 2026-07-24 |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter | Phase 2 | active not recruiting | 2026-07-15 |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | Phase 1 | completed | 2026-01-27 |
| NCT04113122 | Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study | Not applicable | recruiting | 2024-12-13 |
| NCT04259879 | Molecular Pathways Related to Short-term Fasting Response | Not applicable | completed | 2020-02-17 |
| NCT02064244 | Inferior Vena Cava (IVC) Size in Acute Renal Failure | — | completed | 2016-06-09 |
P21 — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: P21 (source record; form not independently established)Average reference mass: 578.7 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about P21
What is P21?+
P21 (P021) is a synthetic peptide designed as a mimetic of an active region of ciliary neurotrophic factor (CNTF). It has been studied in animal models of neurogenesis and cognitive aging and is not authorized as a medicine by Health Canada.
What Canadian product status is recorded for P21?+
Canadian product status for P21 has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of P21?+
P21 is commonly described as approximately 4 amino acids (Research peptide).
Related peptides
References & further reading
- 1.Falangola et al. (2026). Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease. Magn Reson Imaging
- 2.PubMed — Bolognin et al., rescue of cognitive-aging with a neurogenic compound (2014, PMID 24702821)
- 3.PubMed — Kazim et al., neurotrophic peptidergic compound in a triple-transgenic AD model (2014, PMID 25046994)